Aug 10, 2022 / 02:30PM GMT
Kyle William Rose - Canaccord Genuity Corp., Research Division - Senior Analyst
Great. Good morning, and welcome back to the 42nd Annual Canaccord Genuity Global Growth Conference. I'm Kyle Rose. I'm one of the medical technology analysts here at Canaccord. Very glad to be back in person and see some faces rather than just Zoom screens.
But I'm joined this morning by Dexcom. Dexcom is a leader and innovator in the design, development and commercialization of continuous glucose monitoring, which has really been one of the largest growth segments within med tech over the course of the last decade. So very pleased to be joined by the CFO, Jereme Sylvain; as well as the Head of Investor Relations, Sean Christensen.
So we've got a fireside chat format here. I've got a list of questions I want to work through. I want to make it as interactive as possible. So raise your hand, and I'll do my best to weave anything in.
And then just before we jump into questions here, just need to give the obligatory compliance disclosures that any disclosures if and where applicable, you can find those
Dexcom Inc at Canaccord Genuity Growth Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers